AcelRx is currently seeking commercial and development partners for DZUVEOTM and for Zalviso® in select geographies. Our ideal partners have both broad geographic coverage and a demonstrated track record of success in our target markets.
We welcome the opportunity to talk with potential commercialization partners worldwide about licensing relationships, development collaborations, and strategic alliances that complement and extend our own development and commercial capabilities.
To discuss potential partnering opportunities, please contact:
DZUVEO (known as DSUVIA™ in the US) is a sublingual sufentanil tablet (30 mcg) delivered via a disposable, prefilled, single-dose applicator. The product is designed to be administered by a healthcare provider for the management of moderate-to-severe acute pain in a variety of medically monitored settings, including emergency medicine; outpatient, short-stay or ambulatory surgery; and non-surgical patients experiencing moderate-to-severe acute pain in the hospital. In April 2018, AcelRx received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for DZUVEO recommending approval in the European Union and European Economic Area for the management of moderate-to-severe acute pain. On June 27th, 2018, DZUVEO received approval from the European Commission (EC) for the management of acute moderate-to-severe pain in adults in medically monitored settings.
Zalviso is currently approved by the European Commission (EC) for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting. It is marketed by Grünenthal Group, AcelRx's licensee in Europe and Australia.